The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …

Parkinson's disease (PD) is the second leading neurodegenerative disease globally,
impacting the quality of life of millions of people. It is estimated that the treatment cost of PD …

Rotigotine (RTG) is an anti-Parkinson's drug approved by the USFDA to treat motor and non-
motor symptoms of both early and advanced stages of the disease. However, issues like …

Parkinson's disease (PD) is a progressive neurodegenerative disease characterized in part
by the deterioration of dopaminergic neurons which leads to motor impairment. Although …

Neurodegenerative disorders (ND), associated with the progressive loss of neurons,
oxidative stress-mediated production of reactive oxygen species (ROS), and mitochondrial …

A wholly new electroanalytical protocol for the sensitive determination of Amisulpride (AMS)
has been developed. AMS is an antipsychotic and antiemetic medicine that is prescribed at …

Background: It is necessary to conduct a meta-analysis of the clinical randomized controlled
trials (RCTs) on ropinirole in the treatment of Parkinson disease (PD), to explore the effects …

Parkinson's disease (PD) is a serious neurodegenerative disease. Most of the current
treatment can only alleviate symptoms, but not stop the progress of the disease. Therefore, it …

Purpose Psychiatric comorbidity in Parkinson's disease (PD) and atypical parkinsonian
syndromes (APS) has been consistently associated with poor outcomes. However, the co …

The symptomatic treatment of Parkinson's disease (PD) has been dominated by the use of
dopaminergic medication, but significant unmet need remains, much of which is related to …